Press Release: BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, t
BridgeBio Pharma Price Target Maintained With a $70.00/Share by Cantor Fitzgerald
BridgeBio Pharma Price Target Maintained With a $70.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on BridgeBio Pharma, Maintains $70 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates BridgeBio Pharma with a Overweight and maintains $70 price target.
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
J.P. Morgan analyst Anupam Rama maintains $BridgeBio Pharma(BBIO.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.8% and a total average return of 5.0% over the
Buy Rating Affirmed for BridgeBio Pharma Amid Market Overreaction and Promising Long-Term Prospects
BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy?
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Raymond James Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $46
Raymond James analyst Danielle Brill maintains $BridgeBio Pharma(BBIO.US)$ with a buy rating, and adjusts the target price from $45 to $46.According to TipRanks data, the analyst has a success rate of
BridgeBio Pharma Is Maintained at Buy by B of A Securities
BridgeBio Pharma Is Maintained at Buy by B of A Securities
BridgeBio Pharma Price Target Cut to $42.00/Share From $50.00 by B of A Securities
BridgeBio Pharma Price Target Cut to $42.00/Share From $50.00 by B of A Securities
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $42
BofA Securities analyst Jason Zemansky maintains $BridgeBio Pharma(BBIO.US)$ with a buy rating, and maintains the target price at $42.According to TipRanks data, the analyst has a success rate of 64.4
Shareholders in BridgeBio Pharma (NASDAQ:BBIO) Have Lost 61%, as Stock Drops 16% This Past Week
If you love investing in stocks you're bound to buy some losers. Long term BridgeBio Pharma, Inc. (NASDAQ:BBIO) shareholders know that all too well, since the share price is down considerably over th
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Cuts Target Price to $42
BofA Securities analyst Jason Zemansky maintains $BridgeBio Pharma(BBIO.US)$ with a buy rating, and adjusts the target price from $50 to $42.According to TipRanks data, the analyst has a success rate
Express News | BridgeBio Pharma Inc : BofA Global Research Cuts Price Objective to $42 From $50
Goldman Sachs Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $50
Goldman Sachs analyst Paul Choi maintains $BridgeBio Pharma(BBIO.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 49.5% and a
ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday.Shares of ResMed Inc. (NYSE:RMD) fell sharply during Monday's session following sleep apnea data from Lilly.Citigro
BridgeBio Pharma Down Over 16%, on Pace for Largest Percent Decrease Since December 2021 -- Data Talk
BridgeBio Pharma, Inc. ( BBIO ) is currently at $22.81, down $4.55 or 16.63% --Would be lowest close since July 14, 2023, when it closed at $18.22 --On pace for largest percent decrease since Dec. 2
TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
TD Cowen analyst Tyler Van Buren maintains $BridgeBio Pharma(BBIO.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 41.5% and a total average return of -1.7% over th
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
H.C. Wainwright analyst Ram Selvaraju maintains $BridgeBio Pharma(BBIO.US)$ with a buy rating, and maintains the target price at $43.According to TipRanks data, the analyst has a success rate of 36.1%